This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bishop, E.
Right arrow Articles by Grayson, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bishop, E.
Right arrow Articles by Grayson, M. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2006, p. 1599-1602, Vol. 50, No. 4
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.4.1599-1602.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Good Clinical Outcomes but High Rates of Adverse Reactions during Linezolid Therapy for Serious Infections: a Proposed Protocol for Monitoring Therapy in Complex Patients

Emma Bishop,1* Sharmila Melvani,1 Benjamin P. Howden,1,4 Patrick G. P. Charles,1,2 and M. Lindsay Grayson1,2,3*

Infectious Diseases Department, Austin Health, Heidelberg, Victoria, Australia,1 Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia,2 Department of Epidemiology & Preventive Medicine,3 Microbiology Department, Monash University, Melbourne, Victoria, Australia4

Received 1 August 2005/ Returned for modification 11 October 2005/ Accepted 2 February 2006

We assessed the toxicity and clinical outcomes associated with linezolid therapy (mean duration, 29 ± 28 days; range, 8 to 185 days) in 44 patients with serious gram-positive infections. Although a clinical cure was achieved in 73% of the cases, 28/44 (64%) had adverse reactions (thrombocytopenia, n = 13; anemia, n = 7; gastrointestinal, n = 12; peripheral neuropathy, n = 1; serotonin syndrome, n = 1), such that a systematic monitoring protocol was developed.

* Corresponding author. Mailing address for M. Lindsay Grayson: Infectious Diseases Department, Austin Health, Studley Rd., Heidelberg, Victoria 3084, Australia. Phone: (613) 9496-5000. Fax: (613) 9496-6677. E-mail: Lindsay.Grayson{at}austin.org.au. Mailing address for Emma Bishop: Infectious Diseases Department, Austin Health, Studley Rd., Heidelberg, Victoria 3084, Australia. Phone: (613) 9496-6676. Fax: (613) 9496-6677. E-mail: Emma.Bishop{at}austin.org.au.

Antimicrobial Agents and Chemotherapy, April 2006, p. 1599-1602, Vol. 50, No. 4
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.4.1599-1602.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Livermore, D. M. (2008). Future directions with daptomycin. J Antimicrob Chemother 62: iii41-iii49 [Abstract] [Full Text]  
  • Louie, A., Heine, H. S., Kim, K., Brown, D. L., VanScoy, B., Liu, W., Kinzig-Schippers, M., Sorgel, F., Drusano, G. L. (2008). Use of an In Vitro Pharmacodynamic Model To Derive a Linezolid Regimen That Optimizes Bacterial Kill and Prevents Emergence of Resistance in Bacillus anthracis. Antimicrob. Agents Chemother. 52: 2486-2496 [Abstract] [Full Text]  
  • REHM, S. J. (2008). Staphylococcus aureus: The new adventures of a legendary pathogen. Cleveland Clinic Journal of Medicine 75: 177-192 [Abstract] [Full Text]  
  • Corbett, S. M., Rebuck, J. A. (2008). Medication-Related Complications in the Trauma Patient. J Intensive Care Med 23: 91-108 [Abstract]  
  • Robicsek, A., Suseno, M., Beaumont, J. L., Thomson, R. B. Jr., Peterson, L. R. (2008). Prediction of Methicillin-Resistant Staphylococcus aureus Involvement in Disease Sites by Concomitant Nasal Sampling. J. Clin. Microbiol. 46: 588-592 [Abstract] [Full Text]  
  • de Jesus Valle, M. J., Uranga, N. S., Lopez, F. G., Hurle, A. D.-G., Navarro, A. S. (2007). Disposition of linezolid in the isolated rat lung after systemic and pulmonary drug delivery. J Antimicrob Chemother 60: 1074-1079 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»